Tag Archives: SNY

Best Low Price Stocks To Buy Right Now

In my very first MannKind article I offered for my SA readers, I made the following statement:

Wall Street gurus are always smarter than the retail investor that doesn’t do their homework.

I have mentioned several times that MannKind’s (NASDAQ:MNKD) management understands the reality and has done a remarkable job in keeping the company hooked up to a life support system....More>>>

Top 10 Clean Energy Stocks To Watch For 2018

One of the richest men in China has made a big bet on an icon of Europe’s automotive industry.

Li Shufu, the billionaire chairman of Chinese car maker Geely (GELYF), invested about $9 billion buying a stake of almost 10% in Daimler (DDAIF), making him the biggest single shareholder in the owner of Mercedes Benz.

Li, who’s estimated to be worth around $18 billion, has....More>>>

Top Bank Stocks For 2018

We all know financial stocks have gone through the roof since President Trump’s win. So the question becomes: what do we do with these companies now?

There’s no one answer for every financial stock, of course.

Some are still great, undervalued buys—but there are two that have gotten grossly overvalued and should be avoided, or sold if you hold them. (Below, I’ll....More>>>

Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments

Analysis focus: GALT

Galectic (NASDAQ:GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genfit and Intercept, it targets a more difficult area of NASH, namely cirrhosis and fibrosis, and....More>>>

Hot Blue Chip Stocks To Own For 2019

Its a snoozefest.

The S&P 500 is stuck in its narrowest range in nearly half a century and trading volume is plumbing multi-month lows. But by September, investors may be pining for the dog days of summer, with data suggesting that it is historically the worst month for stocks.

Since 1928, the S&P 500 has dropped in September 56% of the time, according to Bank of America Merrill....More>>>

Is Esperion Therapeutics Inc. a Buy on the Dip?

Heart diseasestill claims the lives of around 600,000 Americans every year, and uncontrollable cholesterol plays a big role.EsperionTherapeutics Inc. (NASDAQ:ESPR)became oneof2017’s best-performing biotech stocks because it’s developing a drug that could lower this number.

Unfortunately, Esperion recently revealed some disturbing safety data from one of several ongoing late-stage....More>>>

Top 10 Value Stocks To Watch For 2019

&l;p&g;Brad Garlinghouse

CEO, Ripple

&l;b&g;Crypto Net Worth: $400 million-$500 million*&l;/b&g;

&l;img class=&q;dam-image bloomberg size-large wp-image-39744127&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/39744127/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Ripple CEO Brad Garlinghouse / Tony Avelar/Bloomberg

This Harvard....More>>>

Top Safest Stocks To Own Right Now

President Trump took credit Tuesday for “the safest year on record” for U.S. air travel, touting zero deaths in 2017. But there actually haven’t been any deaths on a U.S. passenger airline in nearly nine years.

Still, the president took credit for the safety record in a tweet.

“Since taking office I have been very strict on Commercial Aviation. Good news....More>>>

Are These Disappointing Drugs Back on Track to Billions?

When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers....More>>>